Outcomes in COVID-19 gabapentin studies

0 0.5 1 1.5+ All studies -11% 1 129 Improvement, Studies, Patients Relative Risk Hospitalization -11% 1 129 RCTs -11% 1 129 Late -11% 1 129 Gabapentin for COVID-19 c19early.org November 2025 Favorsgabapentin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -11% 1.11 [0.94-1.32] hosp. time 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Late treatment -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk All studies -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk 1 gabapentin COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors gabapentin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -11% 1.11 [0.94-1.32] hosp. time 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Late treatment -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk All studies -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk 1 gabapentin COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 1 OT: comparison with other treatment Favors gabapentin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -97% 1.97 [1.61-2.40] no recov. 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment -97% 1.97 [1.61-2.40] 76 (n) 53 (n) 97% higher risk All studies -97% 1.97 [1.61-2.40] 76 (n) 53 (n) 97% higher risk 1 gabapentin COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 1 OT: comparison with other treatment Favors gabapentin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -11% 1.11 [0.94-1.32] hosp. time 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Late treatment -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk All studies -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk 1 gabapentin COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors gabapentin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -11% 1.11 [0.94-1.32] hosp. time 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Late treatment -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk All studies -11% 1.11 [0.94-1.32] 76 (n) 53 (n) 11% higher risk 1 gabapentin COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors gabapentin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Soltani (RCT) -11% 1.11 [0.94-1.32] hosp. time 76 (n) 53 (n) OT​1 Improvement, RR [CI] Treatment Control Soltani (RCT) -97% 1.97 [1.61-2.40] no recov. 76 (n) 53 (n) OT​1 Soltani (RCT) -66% 1.66 [1.36-2.02] no recov. 76 (n) 53 (n) OT​1 Gabapentin COVID-19 outcomes c19early.org November 2025 1 OT: comparison with other treatment Favors gabapentin Favors control